RSS Feed Print
Invitation to AD PACE Virtual Plenary Sessions - Using Patient and Caregiver Data to Inform Drug Development and Access, July 16th - 17th
Michael Ellenbogen
Posted: Friday, July 10, 2020 12:10 PM
Joined: 11/30/2011
Posts: 4272


On July 16 and 17, UsAgainstAlzheimer’s Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative will hold a two-day workshop – The Science of the Alzheimer’s Lived Experience: Using Patient and Caregiver Data to Inform Drug Development and Access. On behalf of the AD PACE Co-Chairs, George Vradenburg and Meryl Comer, (and myself as an AD PACE executive steering committee member) we invite you to join us for the morning plenary sessions, which will feature presentations by leaders in patient focused drug development and patient experience data. Please refer to the invitation, attached below, for further details and to register for these sessions. We encourage you to share this invitation with your colleagues.

 

 

 

 

https://f.datasrvr.com/f1/620/99133/Ad-pace_email-header_v4.jpg

http://t.contentsvr.com/space.gif

 

The Science of the Alzheimer’s Lived Experience: Using Patient and Caregiver Data to Inform Drug Development and Access


http://t.contentsvr.com/space.gif

 

On July 16-17, the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE), an initiative of UsAgainstAlzheimer’s, will hold a two-day virtual workshop to gain insights and ideas on how to best use data from people living with Alzheimer’s and their care partners in drug development and health care delivery.

The goal of this workshop is to create a shared understanding of options – for pre-competitive collaboration – to ensure that drug development and health care delivery decisions are made based on an understanding of what matters most to the people affected.

We invite you to join us for the opening plenary sessions on each day of this AD PACE Ideation Workshop. We believe these opening remarks, presentations and discussions will be of broad interest.

Please indicate your intention to join us for the following events by registering below.

 



July 16th | 9:00 – 10:40 AM: Vision for the Future of Patient-Focused Drug Development in Alzheimer’s. Opening session featuring keynote addresses and a fireside chat with: 

  • Janet Woodcock, Director of FDA’s Center for Drug Evaluation and Research
  • Congresswoman Diana DeGette (D-CO), co-sponsor with Fred Upton (R-MI) of the 21st Century Cures Act (2015), with version “2.0” proposed for introduction later this year
  • Goldie Smith Byrd, Director of the Maya Angelou Center for Health Equity and Professor of Social Sciences and Health Policy at Wake Forest University


July 17th | 9:00 – 10:40 AM: Building Optimal Uses for the Science of the Lived Experience with Alzheimer’s in the Post Approval Environment. Featuring keynote addresses and a fireside chat with: 

  • Sean Tunis, former CMS Chief Medical Officer and Founder of the Center for Medical Technology Policy
  • Sudhir Sivakumaran, Executive Director of C-PATH Critical Path for Alzheimer’s Disease (CPAD)
 

 

 

http://t.contentsvr.com/space.gif

http://t.contentsvr.com/space.gif

 

http://t.contentsvr.com/space.gif

 

 

We look forward to hearing from you and hope you are able to join us for both of these events. This invitation is transferable, so please share with those in your organization who may wish to attend.

UsAgainstAlzheimer’s

George Vradenburg and Meryl Comer, Co-Chairs of AD PACE


QUESTIONS? Please contact Sanjyot Sangodkar or call +1 202 312 7441.

 


 

GUEST SPEAKERS

https://f.datasrvr.com/f1/420/83396/Goldie_Smith_Byrd.jpg

 

https://f.datasrvr.com/f1/620/51013/DeGette.jpg

         

Goldie Smith Byrd, PhD
Director, Maya Angelou Center
for Health Equity; Professor,
Social Sciences and Health Policy
at Wake Forest University

 

Dianna DeGette (D-CO)
U.S. Representative,
Colorado’s First
Congressional District

         

https://f.datasrvr.com/f1/520/45718/Sivakumaran.jpg

 

https://f.datasrvr.com/f1/020/79059/Sean_Tunis_HiRes.jpg

         

Sudhir Sivakumaran, PhD
Executive Director,
C-Path Critical Path for
Alzheimer’s Disease (CPAD)

 

Sean Tunis M.D., MSc
Founder, Center for Medical Technology Policy (CMTP); Principal, Rubix Health

         

https://f.datasrvr.com/f1/020/94578/Woodcock.jpg

     

Janet Woodcock M.D.
Director, Center for Drug
Evaluation and Research
(CDER), FDA

 

 

 

       

Legal Notice & Disclaimers

 


Michael Ellenbogen
Posted: Thursday, July 16, 2020 8:07 AM
Joined: 11/30/2011
Posts: 4272


 On right now. 


jfkoc
Posted: Thursday, July 16, 2020 11:03 AM
Joined: 12/4/2011
Posts: 20782


thanks